• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Treace Announces First Annual National Bunion Day

    4/16/24 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email

    PONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the first-ever National Bunion Day in the United States. National Bunion Day is an opportunity to help more people learn about the identification and treatment of this common bone deformity in the foot, which often includes debilitating pain for millions of adults in the U.S. Approximately one in four U.S. adults alone develop the bunion deformity in their lifetime.1

    National Bunion Day

    As the leader in 3D bunion correction, Treace is uniquely positioned to drive greater patient education and awareness of the Lapiplasty® procedure, the #1 most commonly used 3D bunion correction procedure chosen by U.S. surgeons.2 As part of National Bunion Day, Treace is sponsoring a broad-based awareness and information campaign to address misconceptions and stigma associated with bunions. The awareness campaign includes a series of new educational materials, online events, opportunities for patients to share their experiences in traditional and social media, and physician outreach. April also marks National Foot Health Awareness Month, an opportunity to set a strong foundation of bunion education and awareness. The month-long effort calls on all followers to stand up against the stigma surrounding bunions, fostering a community of support.

    "Since our first surgical cases in 2015, Treace has been committed to developing innovative treatment options for patients living with bunions and other midfoot deformities, but issues in foot health and bunion treatment have remained under the radar despite the fact that they affect millions of people," said John T. Treace, CEO and Founder of Treace. "Our establishment of National Bunion Day is a reflection of our dedication to the patient communities we serve, and the launch of our new national campaign is designed to erase the stigma and misinformation surrounding bunions and to expand our support for both patients and clinicians through our awareness and educational initiatives. The Lapiplasty® 3D Bunion Correction® Procedure, pioneered by Treace, is designed to minimize recovery time, provide lasting relief from bunion pain, reduce recurrence rates, and improve patient outcomes. We look forward to reaching even more people and raising awareness of the impact that effective bunion treatment can have on the quality of life for patients."

    "Our practice is proud to offer the Lapiplasty® 3D Bunion Correction® Procedure to our patients, who often live with bunion pain for months or even years because of the stigma surrounding the condition," stated Paul Dayton, DPM, MS, FACFAS, of the Foot & Ankle Center of Iowa and one of the original design surgeons for the Lapiplasty® Procedure.3 "The establishment of National Bunion Day will bring attention to this common and disruptive health issue, educate patients about the latest treatment options that are designed to get them back to the activities they enjoy and dismantle the stigma surrounding this condition."

    Founded by Treace, National Bunion Day will be held each year on the third Tuesday of April. Updates on activities planned for National Bunion Day are available on the official National Bunion Day webpage at www.lapiplasty.com/NationalBunionDay.

    Those living with bunion pain are encouraged to speak with their healthcare professional about available treatment plans and whether the Lapiplasty® Procedure is right for them. Individual results and recovery times may vary. More information about the Lapiplasty® Procedure, including benefits, risks, and recovery, is available at https://www.lapiplasty.com/.

    About Bunions and the Lapiplasty® 3D Bunion Correction® Procedure   

    Bunions are complex bone deformities that result from an unstable joint in the midfoot4 and are frequently marked by a large bump on the side of the big toe. While many believe they are caused by wearing high heels or narrow shoes, bunions affect both men and women of all ages and are often caused by genetic factors.4,5 Bunion deformities are progressive and may lead to arthritis, hammertoes, bone spurs, pain, swelling and numbness that may have a significant impact on mobility and quality of life.4,6 Many people may be reluctant to seek treatment for bunions due to common misconceptions surrounding treatment approaches.

    The Lapiplasty® 3D Bunion Correction® Procedure allows surgeons to correct all three planes of the bunion deformity and address its root cause by securing the unstable joint in the middle of the foot using a patented combination of instruments, implants and surgical methods. By facilitating a comprehensive, 3D correction of the bunion deformity, the Lapiplasty® Procedure allows most patients to quickly return to bearing weight in a surgical boot within two weeks after surgery and get back to their active lifestyle with a low recurrence rate of only 0.9% to 3.2% as demonstrated in studies at 17- and 13-months follow-up, respectively.7,8

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company's expectations that it will reach even more people during National Bunion Day and raise awareness of the impact that effective bunion treatment can have on the quality of life for patients. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace's public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

    Internet Posting of Information

    Treace routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

    About Treace Medical Concepts

    Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

    To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook and Instagram.

    1 Nix S, et al. J Foot Ankle Res. 2010. 27:3:21.

    2 TMC Data on File (AOFAS Member Survey August 2023).

    3 Paul Dayton, DPM, is a member of Treace's Surgeon Advisory Board and a paid consultant for Treace.

    4 American College of Foot and Ankle Surgeons (ACFAS) Website

    5 WebMD Website

    6 American Academy of Orthopedic Surgeons (AAOS) Website

    7 Dayton P, et al. J Foot Ankle Surg. 2019. 58:427-433.

    8 Ray J, et al. Foot Ankle Int. 2019 Aug;40(8):955-960.

    Contacts:

    Treace Medical Concepts, Inc.

    Julie Dewey, IRC

    Chief Communications & Investor Relations Officer

    [email protected] | 209-613-6945

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2d0d0b1a-431e-440f-9da7-2ddbbf022a7d



    Primary Logo

    Get the next $TMCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    11/7/2025$5.00Neutral → Underweight
    Analyst
    11/7/2025Buy → Neutral
    BTIG Research
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    More analyst ratings

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Scanlan Sean F. exercised 16,875 shares at a strike of $1.05, increasing direct ownership by 2% to 706,474 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    2/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Scanlan Sean F. exercised 53,500 shares at a strike of $0.72 and was granted 262,500 shares, increasing direct ownership by 85% to 689,599 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:05 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. covered exercise/tax liability with 14,254 shares and was granted 250,000 shares, increasing direct ownership by 3% to 7,011,633 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology

    PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace's market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, precisely correct in all three planes, and further streamline procedural workflow with Treace's SpeedPlate® Rapid Compression Fixation technology. "As the pioneers and leaders in instrumen

    1/8/26 4:05:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Treace Medical Concepts downgraded by Analyst with a new price target

    Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:29:21 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts downgraded by BTIG Research

    BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

    11/7/25 8:29:10 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts upgraded by BTIG Research with a new price target

    BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

    2/4/25 7:10:07 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    SEC Filings

    View All

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    2/12/26 5:57:53 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    1/13/26 8:54:59 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    12/18/25 8:44:09 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/4/25 6:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    9/17/24 5:17:19 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    8/19/24 9:00:08 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Financials

    Live finance-specific insights

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Reports Third Quarter 2025 Financial Results

    PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $50.2 million in third quarter 2025 representing growth of 11% over the same period in 2024. Reported third quarter 2025 net loss of $(16.3) million and improved adjusted EBITDA by 49% to $(2.6) million in the third quarter 2025 compared to $(5.1) million in the same period in 2024.Presented clinical data at the American

    11/6/25 4:05:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    View All

    Treace Appoints Guy Guglielmino as Chief Commercial Officer

    PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

    12/2/24 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

    PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

    8/21/23 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

    PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

    7/12/23 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

    SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/12/24 6:01:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/8/24 3:44:13 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care